BeOne’s Brukinsa succeeds in frontline mantle cell lymphoma study

June 30, 2026 06:00 AM EDTUpdated 06:26 AM R&DPharma BeOne’s Brukin­sa suc­ceeds in front­line man­tle cell lym­phoma study Lei Lei Wu News Reporter BeOne Med­i­cines said its BTK in­hibitor Brukin­sa cut the risk of dis­ease pro­gres­sion or death by 43% com­pared to chemoim­munother­a­py when used as a first … Sign up to read this article for free. Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox. SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER